Quantcast
Last updated on April 17, 2014 at 8:38 EDT

Latest dyskinesia Stories

2014-04-10 08:28:50

DUODOPA improves quality of life for those with advanced stages of disease MONTREAL, April 10, 2014 /CNW/ - AbbVie today announced that a new treatment called DUODOPA(® )(levodopa/carbidopa intestinal gel) is now available to Canadians with advanced Parkinson's disease. Currently, more than 100,000 Canadians live with Parkinson's - a progressive, incurable neurological disorder that can significantly affect the quality of life of patients, their families and caregivers. DUODOPA is approved...

2014-02-25 08:31:24

DATA FROM KINECT 1 AND KINECT 2 STUDIES WILL BE PRESENTED SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that two NBI-98854 scientific abstracts have been accepted for the scientific program at the 2014 Annual Congress of Parkinson's Disease and Movement Disorders, to be held June 8-12, 2014 in Stockholm Sweden. This annual meeting draws over 5,000 experts from around the world to address current topics related to movement...

2014-01-29 12:27:59

NEW YORK, Jan. 29, 2014 /PRNewswire-USNewswire/ -- Research projects from three biopharmaceutical companies in the United States comprise the 2013 second half (2H 2013) of The Michael J. Fox Foundation for Parkinson's Research (MJFF) Partnering Program. Among the most promising in the MJFF portfolio, Partnering Program participants' research projects are presented directly to industry groups who may wish to invest in further development of the project. By connecting industry leaders...

2014-01-08 23:04:51

Catalent Pharma Solutions, the global leader in development solutions and advanced delivery technologies for drug, biologic and consumer health products, and Adamas Pharmaceuticals Inc., today announced an agreement for Phase 3 clinical trials manufacturing of ADS-5102 (amantadine HCl) extended release capsules, an investigational treatment being developed for Levodopa-Induced Dyskinesia (LID) in patients with Parkinson’s disease. Somerset, NJ (PRWEB) January 08, 2014 Catalent Pharma...

2013-10-22 08:33:22

ALISO VIEJO, Calif., Oct. 22, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the enrollment of the first patient in study AVR-133. The study is a proof of concept, Phase II clinical trial investigating the use of AVP-923 for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease (PD). (Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO) "This is an important study of a compound with multifaceted...

2013-10-02 12:29:35

Results from the Phase 2/3 EASED Trial Demonstrate an Increase of Approximately Three Hours in ON Time Without Troublesome Dyskinesia for Patients Taking ADS-5102 Compared to Placebo MONTREAL and EMERYVILLE, Calif., Oct. 2, 2013 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. presented positive results today from the Phase 2/3 EASED((TM)) clinical trial of ADS-5102 at the World Parkinson's Congress. ADS-5102 is Adamas' proprietary long-acting capsule formulation of amantadine HCl in development...

2013-07-01 16:26:33

Phase IIB Study Evaluating Twelve Weeks of Continuous Dosing With NBI-98854 SAN DIEGO, July 1, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has completed recruitment in the Phase IIb clinical trial (Kinect Study) of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The final subject will randomize this week. The design of this twelve-week Phase IIb study is a randomized, parallel, double-blind, placebo-controlled...

2013-06-19 00:20:46

MILAN, June 19, 2013 /PRNewswire/ -- Safinamide significantly improves responder rates in fluctuating Parkinson's disease (PD) patients as add-on to levodopa Safinamide is associated with clinically important improvement in motor symptoms in fluctuating PD patients as add-on to levodopa Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its...

2013-06-18 08:30:54

SYDNEY, Australia And EMERYVILLE, Calif., June 18, 2013 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. presented final results today from a Phase 2/3 clinical trial of ADS-5102 (amantadine HCl extended release) capsules demonstrating a statistically significant improvement in levodopa-induced dyskinesia (LID) as measured by change from baseline at week 8 versus placebo in the Unified Dyskinesia Rating Scale (UDysRS). ADS-5102 is Adamas' investigational extended-release formulation of amantadine...

2013-06-10 08:30:20

Study Data to be Presented at 17th International Congress of Parkinson's Disease and Movement Disorders EMERYVILLE, Calif., June 10, 2013 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. announced today that the Company's Phase 2/3 EASED((TM)) (Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia) clinical trial of ADS-5102 (Nurelin((TM)); amantadine HCl extended release) met the study's primary endpoint. ADS-5102 is an investigational...